Evidence map›Paper›PMID 31719544›Full record

ArticleScientific reports2019

Effects of combined D-fagomine and omega-3 PUFAs on gut microbiota subpopulations and diabetes risk factors in rats fed a high-fat diet.

Mercè Hereu, Sara Ramos-Romero, Cristina Busquets, Lidia Atienza, Susana Amézqueta, Bernat Miralles-Pérez, Maria Rosa Nogués, Lucía Méndez, Isabel Medina, Josep Lluís Torres

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 20 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Mercè HereuInstitute of Advanced Chemistry of Catalonia (IQAC-CSIC), Barcelona, Spain.
Sara Ramos-RomeroInstitute of Advanced Chemistry of Catalonia (IQAC-CSIC), Barcelona, Spain. sara.ramos@iqac.csic.es.
Cristina BusquetsInstitute of Advanced Chemistry of Catalonia (IQAC-CSIC), Barcelona, Spain.
Lidia AtienzaDepartment of Pathology Puerta del Mar University Hospital, Cádiz, Spain.ORCID http://orcid.org/0000-0002-7349-8802
Susana AmézquetaDepartament d'Enginyeria Química i Química Analítica and Institut de Biomedicina (IBUB), Universitat de Barcelona, Barcelona, Spain.
Bernat Miralles-PérezUniversitat Rovira i Virgili, Unitat de Farmacologia, Facultat de Medicina i Ciències de la Salut, Reus, Spain.
Maria Rosa NoguésUniversitat Rovira i Virgili, Unitat de Farmacologia, Facultat de Medicina i Ciències de la Salut, Reus, Spain.
Lucía MéndezInstituto de Investigaciones Marinas (IIM-CSIC), Vigo, Spain.
Isabel MedinaInstituto de Investigaciones Marinas (IIM-CSIC), Vigo, Spain.
Josep Lluís TorresInstitute of Advanced Chemistry of Catalonia (IQAC-CSIC), Barcelona, Spain.
Institute of Advanced Chemistry of Catalonia · ESInstituto de Investigacións Mariñas · ESUniversitat Rovira i Virgili · ESHospital Universitario Puerta del Mar · ESUniversitat de Barcelona · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Food contains bioactive compounds that may prevent changes in gut microbiota associated with Westernized diets. The aim of this study is to explore the possible additive effects of D-fagomine and ω-3 PUFAs (EPA/DHA 1:1) on gut microbiota and related risk factors during early stages in the development of fat-induced pre-diabetes. Male Sprague Dawley (SD) rats were fed a standard diet, or a high-fat (HF) diet supplemented with D-fagomine, EPA/DHA 1:1, a combination of both, or neither, for 24 weeks. The variables measured were fasting glucose and glucose tolerance, plasma insulin, liver inflammation, fecal/cecal gut bacterial subgroups and short-chain fatty acids (SCFAs). The animals supplemented with D-fagomine alone and in combination with ω-3 PUFAs accumulated less fat than those in the non-supplemented HF group and those given only ω-3 PUFAs. The combined supplements attenuated the high-fat-induced incipient insulin resistance (IR), and liver inflammation, while increasing the cecal content, the Bacteroidetes:Firmicutes ratio and the populations of Bifidobacteriales. The functional effects of the combination of D-fagomine and EPA/DHA 1:1 against gut dysbiosis and the very early metabolic alterations induced by a high-fat diet are mainly those of D-fagomine complemented by the anti-inflammatory action of ω-3 PUFAs.

Indexed as

AnimalsBlood GlucoseDiet, High-FatDrug Therapy, CombinationFatty Acids, Omega-3Gastrointestinal MicrobiomeGlucose Tolerance TestImino PyranosesInsulinLeptinMalePrediabetic StateRatsRats, Sprague-DawleyRisk FactorsBlood GlucosefagomineFatty Acids, Omega-3Imino PyranosesInsulinLeptin

Identifiers

PMID31719544
PMCPMC6851385
OpenAlexW2985572317

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.